45 results about "Tumor resection" patented technology

The invention relates to an estrogen receptor alpha and fibroblast activating protein dual-targeting near-infrared fluorescent probe as well as a preparation method and medical application thereof. Specifically, the probe can be used as a fluorescence probe for developing cells co-expressing the estrogen receptor alpha and the fibroblast activating protein, and can also be used as a near-infrared fluorescence imaging probe for diagnosing benign / malignant lesions such as nodules / tumors co-expressing the estrogen receptor alpha and the fibroblast activating protein. The fluorescent probe can also be applied to research on related biological events in cells for co-expressing the estrogen receptor alpha and the fibroblast activating protein, and particularly can be applied to fluorescent navigation in tumor resection operations for co-expressing the estrogen receptor alpha and the fibroblast activating protein; particularly, the composition can be applied to the synergistic treatment of an anti-estrogen therapy and a photodynamic therapy on a diseased region which co-expresses the estrogen receptor alpha and the fibroblast activating protein.

The present application relates to providing a doxorubicin-loaded anti-tumor hemostatic microsphere constructed by a simple, safe and low-cost method and its preparation and application, the doxorubicin-loaded anti-tumor hemostatic microsphere comprises alginate, hemostatic component A, doxorubicin or doxorubicin liposome, crosslinking agent, the hemostatic component A is selected from one or more of carboxymethyl chitosan, hyaluronic acid, collagen, silk fibroin, solve the practical pain point problems such as easy bleeding in tumor resection surgery, large toxicity of chemotherapeutic drugs, large drug dose, frequent drug administration, etc., realize rapid hemostasis in operation, postoperative precise targeted drug delivery, reduce toxic side effects, long-acting drug sustained release, at the same time, all components of the system are safe and reliable, and have good biocompatibility.

The invention relates to a compound as shown in a formula (I) and / or a formula (II) and / or a formula (III) or a tautomer or pharmaceutically acceptable salt thereof, a preparation method and application of the compound or the tautomer or the pharmaceutically acceptable salt in medicine. Specifically, the fluorescent probe can be used as a fluorescent probe for cytological imaging, can also be used as a near-infrared fluorescent imaging probe for diagnosing benign / malignant lesions such as fibrosis, nodules and tumors, and can also be applied to research of related biological events in cytobiology and molecular biology. The fluorescent probe can be particularly applied to fluorescent navigation in tumor resection surgery.

The present invention relates to a method for providing information for predicting the likelihood of bladder cancer recurrence, which provides information that patients who have undergone transurethral resection of a bladder tumor and test positive for suspicious high-grade urothelial carcinoma (SHGUC) or high-grade urothelial carcinoma (HGUC) in a urine cytology test have a higher likelihood of bladder cancer recurrence compared with patients who do not test positive.

The invention discloses an auxiliary operating bed for tumor resection, and relates to the technical field of operating beds, the auxiliary operating bed comprises a bed body, sliding rails are fixedly connected to the two sides of the bed body, a moving frame is slidably connected between the sliding rails, a through groove is formed in the moving frame, a communicating groove is formed in one side of the moving frame, the through groove communicates with the communicating groove, and a liquid spraying pipe penetrates through the moving frame; the lower end of the liquid spraying pipe is fixedly connected with a spraying head, and the liquid spraying pipe is communicated with the spraying head, so that the disinfectant can uniformly cover each corner and surface of the operating bed, the bed body can be comprehensively disinfected without dead angles, microorganisms such as bacteria and viruses on the operating bed can be killed, and the infection risk in the operation process is effectively reduced; and an automatic spraying mode is adopted, the disinfection process can be simplified, the skill requirement and the workload of medical staff are reduced, meanwhile, the situation that repeated disinfection is needed due to incomplete disinfection can be reduced through the uniform spraying effect, and therefore the turnover efficiency of the operating room is improved.

The invention discloses a hepatobiliary tumor resection anesthesia depth management method based on multi-modal monitoring, and relates to the technical field of anesthesia control, and the method comprises the following steps: constructing a multi-source energy sensing zone in the whole operation process of hepatobiliary tumor resection, the electromagnetic radiation track, the sudden change moment of the electroencephalogram signal and the micro-amplitude change of the blood flow signal corresponding to the electrotome starting and stopping process are synchronously collected, and an energy disturbance mapping draft is generated based on the collection result. According to the method, through multi-source energy perception and artifact recognition, precise separation of anesthesia signals and awakening signal reconstruction under electrotome interference are achieved, and the accuracy and continuity of anesthesia depth evaluation are improved; a dynamic traction closed loop of electroencephalogram, blood flow and respiration is established through a self-adaptive slow release mechanism of a delayed release window, so that the anesthesia depth is recovered in a self-steady state, and safety and awakening quality in an operation are guaranteed.

This invention relates to the field of biotechnology, and more particularly to a biomarker, kit, and application for the diagnosis of pancreatic malignant tumors. The biomarker comprises aldehyde-ketone reductase 1B10 protein and carbohydrate antigen 19-9 protein. This biomarker is a secreted serum protein that can specifically distinguish PDAC patients from normal individuals, and from individuals with benign pancreatic diseases, exhibiting high specificity without significant non-specific elevation interference. Combined detection with CA199 can synergistically enhance diagnostic efficacy, significantly reducing the rate of missed diagnoses and misdiagnoses. Simultaneously, this biomarker can assess the postoperative tumor resection effect in PDAC patients, predict whether curative resection is achieved, and provide an effective target for postoperative prognostic monitoring.

The invention belongs to the technical field of medical image processing, and discloses a tumor resection operation planning method and system based on a 3D model, and a storage medium. The method comprises the following steps: obtaining a first medical image and a second medical image, and extracting all blood vessel branch structures in a target organ in each medical image, registering the first medical image and the second medical image based on a common branch structure, generating a third medical image, extracting a tumor area and a blood supply branch connected with the tumor, calculating the shortest distance from the center point of the tumor to the outer surface of the target organ, judging whether the shortest distance is smaller than a first preset value or not, if yes, generating a first surgical area, and if not, generating a second surgical area; and if not, generating a second surgical area, and planning a planned resection range and a surgical approach based on the surgical area. According to the technical scheme, the accuracy and the success rate of the operation can be improved.

The invention relates to drug eluting shape memory foams. Tumorectomy is typically performed to prevent the progression of cancer. However, there is postoperative concern, including the formation of voids that may allow cancer cells to escape at the surgical site, which increases the risk of metastasis. To combat this challenge, embodiments include a polyurethane-based shape memory foam as a tissue void filling device, which can also release an anti-cancer drug. Such foams can be activated at body temperature and become malleable. Such properties may enable the foam to be shaped to precisely seal tissue voids, and then act as a drug eluting device. Based on a pharmaceutical composition having polyvinyl alcohol (PVA), the characteristic of drug release from foam can be varied depending on application.

Provided herein are methods and systems for cancer detection and monitoring. The methods may include minimal residual disease analysis. The methods may include using nucleic acids from a urine sample or a urine cell pellet sample. The methods may include assaying nucleic acids in urine to detect a set of biomarkers from the sample. The methods may include monitoring a subject after transurethral bladder tumor resection.

The invention belongs to the technical field of biomedicine, and particularly relates to a non-small cell lung cancer tissue discrimination model based on differential metabolite combination as well as a construction method and application of the non-small cell lung cancer tissue discrimination model. The differential metabolite combination is composed of lactic acid, phosphoethanolamine, decenoyl carnitine and symmetric dimethylarginine or composed of xanthine, phosphoethanolamine, N-acetyl aspartic acid, decenoyl carnitine and symmetric dimethylarginine, and the determination model establishment method comprises the following steps: collecting and treating a lung cancer tissue sample, carrying out UPLC-HRMS detection, carrying out compound identification, and carrying out quantitative determination. Differential metabolites are screened, key differential metabolites are selected through an LASSO method, the performance of all models based on the key differential metabolites is tested, and the selected optimal model is a logistic regression model. The logistic regression discrimination model based on four or five differential metabolites can effectively distinguish non-small cell lung cancer tumor tissues and normal tissues, and the accuracy, the sensitivity, the specificity, the F1 fraction and the AUC are all greater than 0.8. The model has a small quantity of metabolites, and shows the potential of assisting in clinical detection of non-small cell lung cancer tissues and the potential of assisting surgeons in determining a tumor excision range.

Methods and systems for determining recurrence of a tumor in a subject using mutational profiles derived from cell-free DNA obtained concurrently with or prior to tumor resection and integrating mutational profiles from the resected tumor to enhance classification models. Low-depth whole-genome sequencing data can be used to obtain a variety of molecular profiles, including genetic and epigenetic profiles, from tumor tissue and blood samples obtained after the tumor is resected from the subject. The methods may also comprise using a classifier trained to recognize mutational profiles from subjects exhibiting minimal residual disease (MRD) to determine whether a tumor recurred in a subject.

The invention discloses a glioma operation boundary identification marker and application thereof. The invention confirms that SERPINA3 can be used as a marker for identifying a glioma invasion boundary for the first time, can effectively assist operation planning and tumor excision before or during glioma operation, improves the accuracy of operation excision, provides an effective molecular tool for clinical diagnosis and treatment of glioma, and has a remarkable application prospect.

The invention belongs to the field of medicines, and discloses application of macastine B in preparation of anti-inflammatory, repair-promoting and relapse and metastasis-resisting medicines after liver cancer operation. The invention discloses an application of macastine B in preparation of a medicine for recovering a liver cancer patient after partial liver resection. The macaxantin B can promote liver function recovery, reduce the level of inflammatory factors of liver tissues and serum species, and reduce the tumor recurrence rate and the tumor visceral metastasis rate after tumor excision after an orthotopic liver cancer surgical operation, and compared with simultaneous administration of a liver protection drug and an anti-tumor drug, the macaxantin B has the advantages that the liver metabolism burden is reduced, and the curative effect is improved. And a novel drug treatment choice is provided for disease management of a liver cancer patient in a perioperative period. The invention discloses a medicine for promoting postoperative recovery of an orthotopic liver cancer surgical operation. The medicine comprises an effective therapeutic dose of macastine B and pharmaceutically acceptable auxiliary materials.

A system and method is provided using a healthy side of a brain as tractography quantification standard in surgical planning. Tools are used to compare tractography in the pathological (ipsilateral) hemisphere to the contralateral hemisphere. The tool identifies bundles in the ipsilateral and contralateral hemisphere using surgical planning software that includes an auto-segmentation feature, and provides a ratio of their symmetry, and metric comparison. This gives users a more objective and clinically relevant way of interpreting the results of diffusion quantification. It also provides a metric that can be compared longitudinally as a hemisphere recovers after tumor resection, and brain symmetry is restored.

This invention relates to the field of medical device technology, specifically disclosing a tumor resection device, including a resection mechanism, a body, a handle, a drive mechanism, a transmission mechanism, and an adsorption mechanism. The handle, body, and resection mechanism are sequentially connected. The drive mechanism is installed inside the handle, and the transmission mechanism is installed inside the body and connected to the drive mechanism and the resection mechanism. The drive mechanism drives the resection mechanism to perform tumor resection via the transmission mechanism. The adsorption mechanism is installed inside the handle and body, and when the resection mechanism removes the tumor, the adsorption mechanism removes the removed tumor. The tumor resection device has an elongated structure, and the maximum outer diameter of the cross-section of the tumor resection device is less than or equal to 10 mm. This invention's resection mechanism removes the tumor through the adsorption mechanism, effectively reducing the wound, alleviating patient pain, and lowering surgical risks.

The present invention provides methods for detecting and predicting minimal residual disease in a subject who has undergone tumor resection surgery. Method of the invention utilize a personalized cutoff for determining the likelihood for MRD. In some embodiments, the cutoff is determined on a patient-specific basis and may be used in subsequent assays to analyze samples, evaluate MRD, select therapeutics, and / or evaluate therapeutic efficacy.

The invention relates to the technical field of operation evaluation, in particular to an ultra-low pneumoperitoneum pressure assistance-based laparoscopic operation effect evaluation method, which comprises the following steps of: calling a corresponding expected curative effect benchmark from a historical database on the basis of individual characteristics of a patient; acquiring a dynamic physiological data set of the laparoscopic surgery in real time; identifying an interference type of a non-pneumoperitoneum pressure factor on the dynamic physiological data set, matching a correction algorithm according to the interference type, and correcting the dynamic physiological data by using the correction algorithm to generate corrected physiological data; comparing and analyzing the corrected physiological data with the expected curative effect benchmark to generate an intraoperative safety score; in combination with the deviation degree of the actual postoperative recovery time and the expected recovery time, generating a postoperative recovery efficiency score; and predicting the long-term curative effect offset according to the intraoperative tumor resection quality index, and generating a long-term curative effect benefit score. The reliability of evaluation of the laparoscopic surgery effect can be improved.

The application discloses a kind of near-infrared long afterglow luminescent nano probes, its preparation method and application, belong to near-infrared long afterglow material field. With mesoporous silica as template, with zinc acetate, gallium nitrate, tin chloride, chromium acetate, chromium nitrate and yttrium nitrate as doped metal raw materials, long afterglow luminescent core is obtained by reaction and calcination;The outer layer of long afterglow luminescent core is coated with manganese dioxide, to obtain pre-product;Pre-product is surface modified, and coupling target molecule plerixafor, i.e. near-infrared long afterglow luminescent nano probe. The near-infrared long afterglow luminescent nano probe has good biological safety, can be effectively enriched in the tumor area in vivo after mouse tail vein injection, can realize high-sensitivity imaging of multiple small tumors in vivo under red light LED irradiation, and the imaging time is short, suitable for intraoperative imaging, can be used for the imaging of breast cancer tumor model to guide tumor resection.

1. The name of the design product: bone defect prosthesis. 2. The use of the design product: for repairing large bone defects caused by tumor resection, severe trauma, etc. Through surgical implantation in the affected area, it replaces the missing part of the human bone and restores the normal shape and function of the bone. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: Design 1 Solid Drawing 1. 5. Design 1 is designated as the basic design.

This invention discloses a tumor electric field therapy device and system. The tumor electric field therapy device consists of a frame and electrode modules. The frame forms the skeleton structure of the therapy device, and the electrode modules are attached to the frame. Each electrode module has several electrode contacts, and each electrode contact can be either an active or passive contact. The active contacts can form a circuit with a radio frequency generation module. When the therapy device is implanted into the tumor resection site, all electrode contacts become active contacts, and each electrode contact forms a circuit with the radio frequency generation module, distinguishing between normal tissue and diseased tissue. After distinguishing between normal tissue and diseased tissue, the electrode contacts in the normal tissue area become passive contacts, and the electrode contacts in the diseased tissue area become active contacts, enabling targeted treatment of the diseased tissue and thus reducing the side effects of electric field therapy.

The application belongs to the technical field of biomedical materials, and more particularly relates to a drug-loaded hydrogel for postoperative tumor treatment, a preparation method and application thereof. Two reaction substrates, dopamine and 3-aminobenzene boronic acid, are grafted onto a hyaluronic acid skeleton through an amide condensation reaction by a one-pot method to prepare a hydrogel scaffold material. The flexible rheological properties and excellent biological adhesion can ensure that the hydrogel is stably adhered to the resection wound without displacement, slow and pH-responsive release, and in-vivo drug retention for a long time, so that the hydrogel can respond to the tumor microenvironment and maintain the tumor resection microenvironment at a sufficient drug concentration for a long time. The hydrogel prepared by the application can simultaneously load an antitumor chemotherapeutic drug and a drug capable of improving the tumor microenvironment, so that the tumor microenvironment is significantly improved while the chemotherapeutic drug inhibits the tumor, and the two synergistically promote the intervention and inhibition of postoperative tumor recurrence and metastasis.

The application belongs to the technical field of medical devices, and specifically discloses an anti-tumor electrospun scaffold and a preparation method thereof. The anti-tumor electrospun scaffold comprises a drug-loaded electrospun scaffold body and tumor cell-derived drug-loaded micro-particles loaded on the surface of the scaffold body. The drug-loaded electrospun scaffold body comprises amino polymers, hydrophilic polymers and celecoxib with a mass ratio of (2-10):(2-13):1, which are prepared by using an electrospinning technology, and has a high specific surface area and a high porosity. The loading amount of the tumor cell-derived doxorubicin-loaded micro-particles on the anti-tumor electrospun scaffold is 0.6 μg / mg-6.1 μg / mg. The drug is directly delivered to a tumor resection cavity in the form of in-situ implantation, long-term drug retention, continuous drug release and complete degradation of the scaffold material are achieved. Residual tumor cells are effectively killed, the tumor immune microenvironment is reshaped, and the recurrence and metastasis of the tumor are inhibited.

The invention discloses a brain glioma detection device for mechanical arm assisted light sheet optical coherence elastography, which is characterized in that a millimeter-level air coupling ultrasonic excitation probe and a virtual scanning light sheet probe are jointly integrated to a mechanical arm, and non-destructive and non-contact excitation is performed on brain glioma tissues by utilizing air coupling ultrasound; the scanning light sheet is used for detecting and collecting three-dimensional structure and elasticity modulus information of brain glioma tissues; an integrated mechanical arm is used for clamping an X-ray plate scanning probe to carry out large-range elastic imaging scanning on a suspicious focus area of brain tissue, and mechanical scanning positioning and self-adaptive registration of a three-dimensional structure of the brain tissue are achieved through programming according to irregular morphology characteristics of the brain tissue; according to the system device, use of a coupling agent is avoided, nondestructive, non-contact, high-spatial-resolution and large-view-field-range self-adaptive elastic imaging of the brain glioma boundary is achieved, a doctor can be assisted in tumor excision in an operation, and it is guaranteed that normal brain tissue is not damaged while tumor excision is conducted in the maximum range.

This invention discloses a 3D-printed biodegradable drug-loaded artificial bone repair scaffold, belonging to the field of orthopedic implant technology. The scaffold adopts a gradient porous structure and biodegradable composite material, with internal through-holes and tapered interfaces on the surface, which can load drugs for sustained release. It also has functions of bone induction, anti-infection, mechanical support and prosthesis adaptation, and is suitable for individualized repair of large bone defects after bone tumor resection.

The invention belongs to the mass spectrum technology, and particularly provides a mass spectrum data analysis method and system based on multi-mode perception and intelligent prediction.The analysis method comprises the steps that A1, in the operation, a direct ionization mass spectrometer is used for scanning the surface of an excision cavity, and a metabolite concentration vector is obtained; performing full-field scanning to obtain optical characteristic data; collecting intraoperative image data; a2, performing spatial registration on the obtained multi-modal data, inputting mass spectrum point data into a pre-training model to obtain a pathological state probability, and taking the pathological state probability as anchor point data; a3, performing fusion model adjustment by taking the optical data and the intraoperative image as main input and taking the anchor pathological state as a training label, and outputting a full-field pathological state probability graph; and A4, according to the pathological state probability graph, dividing an excision cavity into a plurality of level areas according to a preset threshold value, overlapping and displaying information of the level areas in a surgical field, and guiding surgical excision. The invention has the advantages of accurate tumor excision and the like.

A magnetic type sterile anti-permeation reusable anti-slip retaining pocket comprises retaining pocket cloth, a surgical operation opening is formed in the retaining pocket cloth, double rows of magnetic buckles are installed at the tail end of the retaining pocket and embedded into the retaining pocket cloth, and the size of the exposed area of a surgical site can be adjusted through magnetic buckling of the magnetic buckles at different positions. Side pockets are arranged on the two sides of the front face of the pocket blocking cloth, and the pocket blocking cloth is of a three-layer structure and comprises bottom-layer twill, middle-layer waterproof cloth and surface-layer twill. The surface layer and the bottom layer of the pocket blocking cloth are made of twill cloth, the middle layer of the pocket blocking cloth is made of waterproof cloth, and the pocket blocking cloth is waterproof, capable of preventing blood pollution, soft in material, convenient to use and capable of being repeatedly used, saves resources, achieves the principle of timely isolation of tumor resection positions and has the effect of preventing tumor diffusion pollution.

Methods for treating and differential diagnosis between ACTH-Dependent and ACTH-Independent Cushing's syndrome are disclosed, in which a glucocorticoid receptor antagonist (GRA) is administered to a Cushing's syndrome patient with a basal ACTH level less than about 25 pg / mL. If i) the patients blood ACTH and ii) the patients blood cortisol, or adrenal hormone, or adrenal pre-hormone levels rise, or if the ACTH:cortisol ratio increases, then ACTH-Dependent Cushing's syndrome is diagnosed. If those levels do not rise, or if the ACTH:cortisol ratio decreases, then ACTH-Independent Cushing's syndrome is diagnosed. In some instances, the patient is recovering from surgery to remove an ACTH secreting tumor, and the method described herein is used to determine if the tumor resection was successful or complete. The GRA may be mifepristone, or a non-steroidal GRA having a heteroaryl-ketone fused azadecalin backbone, an octahydro fused azadecalin backbone, a cyclohexyl pyrimidine backbone, or a fused azadecalin backbone.

The present disclosure relates to the treatment of solid cancers, such as breast cancer, colon cancer, and lung cancer (particularly non-small cell lung cancer (NSCLC)), in human subjects using anti-PD-1 antibodies as monotherapy or as combination therapy with, for example, chemotherapy and / or surgery. The treatments provided may be a combination of tiralizumab and chemotherapy prior to surgery, using different doses of tiralizumab in an auxiliary stage after surgery. Administration regimens may include administration of 200 mg of an anti-PD-1 antibody (e.g., tiralizumab) (e.g., every three weeks) followed by tumor resection, followed by administration of 400 mg of the anti-PD-1 antibody (e.g., every six weeks). Furthermore, the chemotherapy may be platinum-based (e.g., carboplatin and / or cis-platinum), and may further include pemetrexed (e.g., for non-squamous cancer) or paclitaxel (e.g., for squamous cancer).